Veradermics reports positive Phase 3 results for oral baldness pill

Veradermics said its experimental oral formulation of minoxidil met the primary goal of its Phase 3 trial, showing significantly more new hair growth over six months compared with placebo.

The drug, identified as VDPHL01, was also reported to be generally well tolerated, with side effect rates similar to placebo and no heart‑related safety signals.

Analysts called the data a "home run" and the company’s shares jumped up to 48% in morning trading, having risen more than five‑fold since the February IPO.

If regulators approve the pill, it could become the first new oral treatment for male pattern baldness in three decades, entering a market dominated by generics and over‑the‑counter products.